Moderna Inc. (NASDAQ: MRNA) stock is trading lower on Wednesday after the company announced an executive leadership update and highlighted progress across its infectious disease and oncology franchises.
The company added a Chief Operating Officer role to support its increasing scale and diversification. Juan Andres will return to Moderna as COO, effective October 5. Concurrently, Jerh Collins, Chief Technical Operations and Quality Officer, has decided to retire.
Moderna is preparing for the potential launch and scale-up of intismeran autogene following positive Phase 3 results. The company also noted that its infectious disease franchise now includes five approved vaccines. This expansion follows the recent U.S. FDA approval of Moderna’s seasonal flu vaccine and the European Commission marketing authorization of the company’s seasonal flu plus COVID combination vaccine.
In oncology, Moderna released positive topline results from the Phase 3 INTerpath-001 trial of adjuvant treatment with intismeran autogene (intismeran; V940 or mRNA-4157) combined with Keytruda (pembrolizumab) in patients with completely resected stage IIB-IV melanoma. The therapy is an mRNA-based individualized neoantigen therapy designed for each patient based on unique tumor mutations.
Regarding COVID-19 vaccines, the U.S. FDA approved supplemental applications in August for the 2026-2027 formulas for Spikevax and mNEXSPIKE. Spikevax is approved for individuals 6 months through 64 years of age with at least one underlying condition placing them at high risk for severe outcomes, and all adults 65 years of age and older. mNEXSPIKE is approved for individuals 12 through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes, and all adults 65 years of age and older.
At the time of publication, Moderna shares were down 8.23% to $186.70.
